Loading
GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.
Alan Venook is Shorenstein Associate Director for Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center and a long-time investigator with the Alliance for Clinical Trials in Oncology. A medical oncologist in colorectal and liver cancer, he chaired CALGB/SWOG 80405, the first-line trial of cetuximab versus bevacizumab with chemotherapy in KRAS wild-type metastatic colorectal cancer, whose analyses established primary tumour sidedness as a treatment factor. His papers report that trial in JAMA and a pooled analysis of primary tumour side in RAS wild-type disease treated with EGFR directed antibodies across six randomised trials. His work spans colorectal cancer, hepatocellular carcinoma and cooperative group trials aimed at EGFR and VEGF.
It is the strongest evidence that the consensus subtypes could choose between the two first-line biologicals, and the clearest statement of why they have not: it is a retrospective analysis of a subset of one trial, on an assay nobody has validated for clinical use.
The negative counterweight to FIRE-3. The two trials are reconciled only by primary tumour side, which is why the sidedness analysis rather than either trial is what guidelines now cite.
The analysis that put 'left-sided, RAS and BRAF wild-type' into every guideline as the anti-EGFR population, and made an anatomical fact into a treatment-selection biomarker.
Shares Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405), Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, VEGF / VEGFR, EGFR.
Shares Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405, Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405), Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Colorectal cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Annals of Oncology.
Shares VEGF / VEGFR, Hepatocellular carcinoma, Colorectal cancer.
Shares Alliance for Clinical Trials in Oncology, VEGF / VEGFR, EGFR, Colorectal cancer.
Shares VEGF / VEGFR, EGFR, Hepatocellular carcinoma, Colorectal cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Hepatocellular carcinoma.
Shares Alliance for Clinical Trials in Oncology, Colorectal cancer.